Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Period	fcf
2015-12-31	-$38.46M
2016-12-31	-$47.82M
2017-12-31	-$131.32M
2018-12-31	-$148.75M
2019-12-31	-$71.29M
2020-12-31	-$86.05M
2021-12-31	-$263.81M
2022-12-31	-$174.83M
2023-12-31	-$135.49M
2024-12-31	-$23.97M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ESPR	$2.31	-0.22%	3.21M
3
4
5

Esperion Therapeutics Inc. (ESPR) Free Cash Flow

Free Cash Flow Data

Get Esperion Therapeutics Inc. Data in Excel

More ESPR Financial Data